High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS

Arzu Umar; M (Malgorzata) Jaremko; Peter Burgers; Theo Luider; John Foekens; L Pasa-Tolic

doi:10.1586/14789450.5.3.445

High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS

Arzu Umar, M (Malgorzata) Jaremko, Peter Burgers, Theo Luider, John Foekens, L Pasa-Tolic

Research output: Contribution to journal › Article › Academic

5 Citations (Scopus)

Abstract

Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.

Original language	Undefined/Unknown
Pages (from-to)	445-455
Number of pages	11
Journal	Expert Review of Proteomics
Volume	5
Issue number	3
DOIs	https://doi.org/10.1586/14789450.5.3.445
Publication status	Published - 2008

Research programs

EMC MM-03-44-06
EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14789450.5.3.445

http://hdl.handle.net/1765/22142

Cite this

@article{56537caeba964a8bb33a8d627f54486b,

title = "High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS",

abstract = "Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.",

author = "Arzu Umar and Jaremko, {M (Malgorzata)} and Peter Burgers and Theo Luider and John Foekens and L Pasa-Tolic",

year = "2008",

doi = "10.1586/14789450.5.3.445",

language = "Undefined/Unknown",

volume = "5",

pages = "445--455",

journal = "Expert Review of Proteomics",

issn = "1478-9450",

publisher = "Taylor & Francis Ltd",

number = "3",

}

TY - JOUR

T1 - High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS

AU - Umar, Arzu

AU - Jaremko, M (Malgorzata)

AU - Burgers, Peter

AU - Luider, Theo

AU - Foekens, John

AU - Pasa-Tolic, L

PY - 2008

Y1 - 2008

N2 - Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.

AB - Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.

U2 - 10.1586/14789450.5.3.445

DO - 10.1586/14789450.5.3.445

M3 - Article

C2 - 18532912

SN - 1478-9450

VL - 5

SP - 445

EP - 455

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

IS - 3

ER -